MMIRF
Price
$0.08
Change
+$0.07 (+700.00%)
Updated
Jan 14 closing price
Capitalization
63.36M
SRPT
Price
$118.00
Change
+$0.94 (+0.80%)
Updated
Jan 17 closing price
Capitalization
11.27B
45 days until earnings call
Ad is loading...

MMIRF vs SRPT

Header iconMMIRF vs SRPT Comparison
Open Charts MMIRF vs SRPTBanner chart's image
Medmira
Price$0.08
Change+$0.07 (+700.00%)
Volume$11.8K
Capitalization63.36M
Sarepta Therapeutics
Price$118.00
Change+$0.94 (+0.80%)
Volume$649.14K
Capitalization11.27B
MMIRF vs SRPT Comparison Chart
Loading...
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MMIRF vs. SRPT commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MMIRF is a Hold and SRPT is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (MMIRF: $0.08 vs. SRPT: $118.00)
Brand notoriety: MMIRF: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MMIRF: 59% vs. SRPT: 70%
Market capitalization -- MMIRF: $63.36M vs. SRPT: $11.27B
MMIRF [@Biotechnology] is valued at $63.36M. SRPT’s [@Biotechnology] market capitalization is $11.27B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MMIRF’s FA Score shows that 1 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).

  • MMIRF’s FA Score: 1 green, 4 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, MMIRF is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MMIRF’s TA Score shows that 1 TA indicator(s) are bullish while SRPT’s TA Score has 5 bullish TA indicator(s).

  • MMIRF’s TA Score: 1 bullish, 1 bearish.
  • SRPT’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, SRPT is a better buy in the short-term than MMIRF.

Price Growth

MMIRF (@Biotechnology) experienced а +498.47% price change this week, while SRPT (@Biotechnology) price change was -5.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

SRPT is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SRPT($11.3B) has a higher market cap than MMIRF($63.4M). MMIRF YTD gains are higher at: 498.473 vs. SRPT (-2.953). SRPT has higher annual earnings (EBITDA): 187M vs. MMIRF (-2.57M). SRPT has more cash in the bank: 1.2B vs. MMIRF (1.06M). MMIRF has less debt than SRPT: MMIRF (9.54M) vs SRPT (1.4B). SRPT has higher revenues than MMIRF: SRPT (1.64B) vs MMIRF (356K).
MMIRFSRPTMMIRF / SRPT
Capitalization63.4M11.3B1%
EBITDA-2.57M187M-1%
Gain YTD498.473-2.953-16,883%
P/E RatioN/A76.62-
Revenue356K1.64B0%
Total Cash1.06M1.2B0%
Total Debt9.54M1.4B1%
FUNDAMENTALS RATINGS
MMIRF vs SRPT: Fundamental Ratings
MMIRF
SRPT
OUTLOOK RATING
1..100
336
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
82
Overvalued
PROFIT vs RISK RATING
1..100
81100
SMR RATING
1..100
10062
PRICE GROWTH RATING
1..100
3662
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MMIRF's Valuation (4) in the null industry is significantly better than the same rating for SRPT (82) in the Biotechnology industry. This means that MMIRF’s stock grew significantly faster than SRPT’s over the last 12 months.

MMIRF's Profit vs Risk Rating (81) in the null industry is in the same range as SRPT (100) in the Biotechnology industry. This means that MMIRF’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's SMR Rating (62) in the Biotechnology industry is somewhat better than the same rating for MMIRF (100) in the null industry. This means that SRPT’s stock grew somewhat faster than MMIRF’s over the last 12 months.

MMIRF's Price Growth Rating (36) in the null industry is in the same range as SRPT (62) in the Biotechnology industry. This means that MMIRF’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's P/E Growth Rating (99) in the Biotechnology industry is in the same range as MMIRF (100) in the null industry. This means that SRPT’s stock grew similarly to MMIRF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MMIRFSRPT
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
N/A
Bearish Trend 11 days ago
80%
Momentum
ODDS (%)
N/A
Bullish Trend 11 days ago
76%
MACD
ODDS (%)
N/A
Bullish Trend 11 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
56%
Bullish Trend 11 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
69%
Bearish Trend 11 days ago
72%
Advances
ODDS (%)
N/A
Bullish Trend 13 days ago
75%
Declines
ODDS (%)
N/A
Bearish Trend 20 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 11 days ago
74%
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
81%
N/A
View a ticker or compare two or three
Ad is loading...
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DTD77.650.47
+0.60%
WisdomTree US Total Dividend ETF
DNOV43.320.22
+0.51%
FT Vest US Equity Deep Bffr ETF Nov
IDX14.840.07
+0.47%
VanEck Indonesia ETF
TIPZ52.10N/A
+0.01%
PIMCO Broad US TIPS ETF
AGG96.92N/A
N/A
iShares Core US Aggregate Bond ETF

MMIRF and

Correlation & Price change

A.I.dvisor tells us that MMIRF and NWPHF have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MMIRF and NWPHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MMIRF
1D Price
Change %
MMIRF100%
N/A
NWPHF - MMIRF
30%
Poorly correlated
N/A
TECX - MMIRF
29%
Poorly correlated
-2.67%
AZTR - MMIRF
24%
Poorly correlated
-8.18%
SRPT - MMIRF
22%
Poorly correlated
+0.80%
SAGE - MMIRF
22%
Poorly correlated
+1.58%
More

SRPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRPT has been loosely correlated with TECX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SRPT jumps, then TECX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRPT
1D Price
Change %
SRPT100%
+0.80%
TECX - SRPT
59%
Loosely correlated
-2.67%
GLMD - SRPT
51%
Loosely correlated
-1.02%
ALZN - SRPT
49%
Loosely correlated
+0.87%
XBIO - SRPT
48%
Loosely correlated
-0.31%
BMRN - SRPT
45%
Loosely correlated
+0.46%
More